Degarelix Acetate
FDA-approved product (powder, subcutaneous), marketed as Firmagon.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Prostate adenocarcinoma
- Prostate cancer
- Prostate carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other hormone antagonists and related agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA62.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis66.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Degarelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection61.4% AI-predicted activityagainst MRSA50+ registered studies
- ItraconazoleExisting use: Aspergillosis, Blastomycosis, Candidiasis and 4 more61.2% AI-predicted activityagainst MRSA50+ registered studies
- SelpercatinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more61.2% AI-predicted activityagainst MRSA42 registered studies
- Obeticholic AcidExisting use: Biliary liver cirrhosis, Cholangitis, Primary biliary cirrhosis60.9% AI-predicted activityagainst MRSA44 registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more60.8% AI-predicted activityagainst MRSA50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more60.8% AI-predicted activityagainst MRSALab records exist50+ registered studies
- CiclesonideExisting use: Airway obstruction, Allergic rhinitis, Asthma and 3 more60.7% AI-predicted activityagainst MRSA50+ registered studies
- IloperidoneExisting use: Psychosis, Schizophrenia60.6% AI-predicted activityagainst MRSA32 registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more60.6% AI-predicted activityagainst MRSA50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis60.6% AI-predicted activityagainst MRSA28 registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction60.6% AI-predicted activityagainst MRSA50+ registered studies
- EfinaconazoleExisting use: Tinea, Tinea unguium60.5% AI-predicted activityagainst MRSA7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
NCT01220869 · start 2010-12
Registered record
- Registry ID
- NCT01220869
- Conditions
- Prostate Cancer
- Interventions
- Degarelix
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-12
- Completion
- 2012-10
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDegarelixPhasePhase 3Registry statusCompletedA Degarelix Trial in Patients With Prostate Cancer
NCT01242748 · start 2010-10
Registered record
- Registry ID
- NCT01242748
- Conditions
- Prostate Cancer
- Interventions
- Degarelix; Goserelin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2010-10
- Completion
- 2012-01
- Enrolment
- 288
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDegarelix; Goserelin acetatePhasePhase 3Registry statusTerminatedA Trial of Degarelix in Patients With Prostate Cancer
NCT00946920 · start 2009-06
Registered record
- Registry ID
- NCT00946920
- Conditions
- Prostate Cancer
- Interventions
- Degarelix; Goserelin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-06
- Completion
- 2011-03
- Enrolment
- 859
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDegarelix; Goserelin acetatePhasePhase 3Registry statusCompletedExtension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
NCT00117286 · start 2005-03
Registered record
- Registry ID
- NCT00117286
- Conditions
- Prostate Cancer
- Interventions
- Degarelix
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2009-11
- Enrolment
- 57
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDegarelixPhasePhase 2 / Phase 3Registry statusCompletedAn Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
NCT00215683 · start 2005-02
Registered record
- Registry ID
- NCT00215683
- Conditions
- Prostate Cancer
- Interventions
- Degarelix
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2005-02
- Completion
- 2009-11
- Enrolment
- 137
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDegarelixPhasePhase 2 / Phase 3Registry statusCompleted